Virtual Library

Start Your Search

Eirini Maratou



Author of

  • +

    Lunch & Poster Display session (ID 58)

    • Event: ELCC 2019
    • Type: Poster Display session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 4/11/2019, 12:30 - 13:00, Hall 1
    • +

      30P - Prognostic significance of IGF-1 signaling pathway in patients with advanced non-small cell lung cancer (ID 323)

      12:30 - 13:00  |  Author(s): Eirini Maratou

      • Abstract
      • Slides

      Background

      Insulin-like growth factor 1(IGF-1) signaling pathway has been suggested as an important oncogenic mediator in various malignancies, including lung cancer. In this study, we aimed to evaluate serum levels of IGF-1, IGF-2 and IGF-Binding Protein 3 (IGF-BP3) before and after chemotherapy or chemoradiotherapy treatment in patients with locally advanced/metastatic non-small cell lung cancer (NSCLC) and their potential correlation with response to therapy and patient survival.

      a9ded1e5ce5d75814730bb4caaf49419 Methods

      Seventy-three patients with stage III/IV NSCLC were included in the study. Expression of IGF1, IGF2, and IGFBP3 was evaluated in peripheral blood samples in two separate time points, at baseline and 3 months post treatment. Analysis and quantification of circulating levels of IGF-1, IGF-2, IGF-BP3 were performed by total ELISA technique. IGF-1/IGF-BP3 ratio is considered an indicator of IGF-1 bioavailability.

      20c51b5f4e9aeb5334c90ff072e6f928 Results

      In univariate analysis, the median value of IGF-1 after treatment (130.80 vs 98.00 ng/ml, p = 0.087), and the median ratio of IGF-1/IGF-BP3 (0.01044 vs 0.00678, p = 0.056) were higher in responders. Further analysis of the variation of each biomarker before and after treatment showed that the median value of IGF-1 was decreased after treatment in the total population (125.82 from 133.4 ng/ml, p = 0.087), albeit no difference was found between subgroups. In addition, the median value of IGF-1/IGF-BP3 ratio was found to be lower after treatment in the total population (0.01006 from 0.01252, p = 0.011). Importantly, the post-treatment value of the ratio was significantly reduced in responders (0.01044 from 0.01255, p = 0.02). No correlation was found between variation in biomarker values, patient OS and PFS.

      fd69c5cf902969e6fb71d043085ddee6 Conclusions

      In a cohort of patients with stage III/IV NSCLC treated with chemotherapy or chemoradiotherapy, reduction of IGF-1/IGF-BP3 ratio, which is an indicator of IGF-1 bioavailability, was statistically significant in patients that responded to treatment. If validated in larger cohorts, our results support the use of IGF-1/IGFBP3 as a predictive tool for response to chemotherapy in NSCLC.

      b651e8a99c4375feb982b7c2cad376e9 Legal entity responsible for the study

      The authors.

      213f68309caaa4ccc14d5f99789640ad Funding

      Has not received any funding.

      682889d0a1d3b50267a69346a750433d Disclosure

      All authors have declared no conflicts of interest.

      cffcb1a185b2d7d5c44e9dc785b6bb25

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.